Publication date: Aug 01, 2025
Tocilizumab, an anti-inflammatory agent used in severe COVID-19 infection, is known to inhibit the Interleukin 6 receptor and reduce C-reactive protein (CRP) resulting in an increased risk of secondary infections. However, the trend of secondary infection and the relative inflammatory response after tocilizumab use has been reported variably. In this observational cross-sectional study, the time to normalization of CRP, rate of secondary infections, significance of infection indicators (CRP and white blood cell (WBC) count) at the time of secondary infections, length of intensive care unit (ICU) stay, and survival rate were evaluated in patients with severe COVID-19 infection after tocilizumab use. A total of 216 patients (118 tocilizumab receivers vs. 98 nonreceivers) were included in this study. A higher rate of blood-stream infection (p 0. 02), shorter ICU stay (p
| Concepts | Keywords |
|---|---|
| Drugs | C‐reactive protein |
| Inflammatory | secondary infection |
| Stream | tocilizumab |
| Tocilizumab | white blood cell |
| White |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Secondary Infection |
| drug | DRUGBANK | Tocilizumab |
| disease | MESH | COVID-19 |
| disease | MESH | infection |
| disease | IDO | blood |
| disease | IDO | cell |
| disease | IDO | protein |